Crossmark

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) – Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model

Crossref DOI link: https://doi.org/10.1007/s11095-024-03754-7

Published Online: 2024-09-05

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

DiBlasi, Robert M http://orcid.org/0000-0002-9206-7346
KenKnight, Hattie

Kontoudios, Niko

Farkas, Dale

Momin, Mohammad A. M.

Hall, Felicia

Hindle, Michael

Longest, Worth
Funding

Funding for this research was provided by:

Bill and Melinda Gates Foundation (INV-058340)
License Information

Text and Data Mining valid from 2024-09-01

Version of Record valid from 2024-09-05
More Information

Article History

Received: 29 May 2024

Accepted: 26 July 2024

First Online: 5 September 2024

Declarations

:

: All experimental animal procedures were conducted according to the National Institute of Health’s Guide for the Care and Use of Laboratory Animals and approved by the Seattle Children’s Institutional Animal Care and Use Committee (ACUC00693).

: Virginia Commonwealth University is currently pursuing patent protection of formulations, devices, and methods described in this study. If licensed and commercialized, these may provide future financial interest to the authors.

Document is current

Any future updates will be listed below